Anlotinib

Generic Name
Anlotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H22FN3O3
CAS Number
1058156-90-3
Unique Ingredient Identifier
GKF8S4C432
Background

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication

用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Phase 4
Not yet recruiting
Conditions
Advanced NSCLC
Interventions
Drug: Tislelizumab
Drug: Anlotinib
First Posted Date
2024-04-10
Last Posted Date
2024-04-10
Lead Sponsor
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Target Recruit Count
33
Registration Number
NCT06356675

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

First Posted Date
2024-04-09
Last Posted Date
2024-04-09
Lead Sponsor
Army Medical Center of PLA
Target Recruit Count
266
Registration Number
NCT06354530
Locations
🇨🇳

Army Medical Center of PLA, Chongqing, None Selected, China

To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Event-free Lifetime
Interventions
Drug: Anlotinib
First Posted Date
2024-04-08
Last Posted Date
2024-06-21
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
64
Registration Number
NCT06352008
Locations
🇨🇳

Tianiin Medical University Cancer Institute & Hospital, Tianjin, China

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Recruiting
Conditions
Breast Cancer
First Posted Date
2024-04-01
Last Posted Date
2024-04-01
Lead Sponsor
The First Hospital of Jilin University
Target Recruit Count
153
Registration Number
NCT06340165
Locations
🇨🇳

The First Affiliated Hospital of Jilin University, Changchun, Jilin, China

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Anlotinib
Drug: Trastuzumab deruxtecan
First Posted Date
2024-03-26
Last Posted Date
2024-03-26
Lead Sponsor
Fudan University
Target Recruit Count
42
Registration Number
NCT06331169
Locations
🇨🇳

Jian Zhang, Shanghai, Shanghai, China

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Phase 2
Not yet recruiting
Conditions
Melanoma
Interventions
Drug: Cadonilimab
Drug: anlotinib
First Posted Date
2024-03-25
Last Posted Date
2024-03-25
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT06327698

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Not Applicable
Not yet recruiting
Conditions
Small Cell Lung Cancer Recurrent
Interventions
Drug: Irinotecan Liposome
Drug: Anlotinib
First Posted Date
2024-02-14
Last Posted Date
2024-02-14
Lead Sponsor
Fudan University
Target Recruit Count
39
Registration Number
NCT06258642
Locations
🇨🇳

Cancer hospital Fudan University, Shanghai, Shanghai, China

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

First Posted Date
2024-01-25
Last Posted Date
2024-01-25
Lead Sponsor
Peking University
Target Recruit Count
90
Registration Number
NCT06222944
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Sintilimab
Drug: Anlotinib
First Posted Date
2024-01-24
Last Posted Date
2024-01-25
Lead Sponsor
Ningbo No.2 Hospital
Target Recruit Count
30
Registration Number
NCT06221462

The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Not Applicable
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Anlotinib
First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
Ningbo Medical Center Lihuili Hospital
Target Recruit Count
30
Registration Number
NCT06188650
Locations
🇨🇳

Kaitai Liu, Ningbo, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy